Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-2449 in Platinum-resistant Recurrent Ovarian Cancer or Advanced Solid Tumors
NCT06687070Phase 1Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Dec 2024
- Primary completion
- May 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of APG-2449 in ovarian cancer and solid tumor (2 arms), sponsored by Ascentage Pharma. Primary endpoints: Treatment-related adverse events at 1 year and Dose Limiting Toxicity at 28 days. Started Dec 2024; status: recruiting.
02
Drugs
APG-2449
03
Conditions
ovarian cancersolid tumor
Beyond the preview
Go deeper on NCT06687070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06687070.